How the Medications Work
Despite coming from different manufacturers, both drugs function as GLP-1 receptor agonists. Wegovy uses semaglutide, which is a protein-based molecule. Because stomach acid breaks down proteins, patients taking this must take it on an empty stomach in the morning with a strict 30-minute waiting period before eating or drinking. Foundayo is a small molecule, not a peptide. This structural difference allows the drug to pass through the stomach intact regardless of food intake, meaning there are basically no fasting requirements.
Comparing Effectiveness and Side Effects
Clinical trials suggest both drugs deliver similar results regarding weight loss. In trials, adults taking the highest dose of Foundayo lost an average of 27 pounds or 12.4% of their body weight over 72 weeks. Meanwhile, adults taking Wegovy lost an average of 33 pounds or about 14% of their body weight over a 64-week period. However, direct comparison is difficult. Following Foundayo’s approval, Novo Nordisk released data comparing separate studies. The report claimed Wegovy produced “significantly greater weight loss” and noted Foundayo users were four times more likely to stop taking the pill due to side effects.
A spokesperson for Novo Nordisk clarified that the analysis was an “indirect treatment comparison” rather than a head-to-head trial. This distinction is vital because the trials were conducted by the manufacturers of each drug and were not randomized controlled studies run simultaneously. The side effect profiles share many commonalities. Both medications can cause burping, constipation, diarrhea, fatigue, gas, headaches, heartburn, nausea, stomach pain, and vomiting. Foundayo brings additional potential issues like hair loss, indigestion, and a swollen belly. Wegovy carries risks of dizziness, feeling bloated, low blood sugar (specifically for those with type 2 diabetes), a runny nose or sore throat, and stomach flu symptoms.
While the weight loss percentages look similar on paper, the gap between clinical trial conditions and daily reality is significant. The availability of a pill that requires strict fasting protocols presents a logistical hurdle that many patients may find impossible to maintain long-term. Without real-world data showing that these strict adherence requirements don’t lead to users abandoning the treatment entirely, the theoretical advantage of slightly higher efficacy with Wegovy might not translate into better outcomes for the general population. Andrew Giaquinto, a clinical assistant professor, notes that the weight loss difference is very similar between the two. Ultimately, the choice depends on whether a patient values the structure of a daily routine or the flexibility of taking a pill without restrictions.
